Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Dobric I et al
I.SharmaR
When we stratified patients by history of renal disease, the use of the GLP-1 receptor agonist-SGLT-2 inhibitor combination in patients with a history of renal disease was associated with a lower hazard ratio for major adverse cardiovascular events (0.41, 0.18 to 0.94) compared with patients without previous renal disease (0.80, 0.57 to 1.12
doi: 10.3389/fimmu.2025.1482308 Received 18 August 2024 Accepted 02 January 2025 Published 21 January 2025 Volume 16 - 2025 Edited by Pengpeng Zhang, Nanjing Medical University, China Reviewed by Sangsu Bang, Duke University, United States Deron R
For someone who would otherwise take nothing at all because of the needle, an effective pill they will actually use beats an injection they will not
